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Abstract
 
Aims
 
To compare glucose control over 18 months between rosiglitazone oral
combination therapy and combination metformin and sulphonylurea in people
with Type 2 diabetes.
 
Methods
 
RECORD, a multicentre, parallel-group study of cardiovascular
outcomes, enrolled people with an HbA
 
1c
 
 of 7.1–9.0% on maximum doses of
metformin or sulphonylurea. If on metformin they were randomized to add-on
rosiglitazone or sulphonylurea (open label) and if on sulphonylurea to rosiglitazone
or metformin. HbA
 
1c
 
 was managed to 
 
≤
 
 7.0% by dose titration. A prospectively
defined analysis of glycaemic control on the first 1122 participants is reported here,
with a primary outcome assessed against a non-inferiority margin for HbA
 
1c
 
 of 0.4%.
 
Results
 
At 18 months, HbA
 
1c
 
 reduction on background metformin was similar
with rosiglitazone and sulphonylurea [difference 0.07 (95% CI 
 
−
 
0.09, 0.23)%],
as was the change when rosiglitazone or metformin was added to sulphonylurea [0.06
(
 
−
 
0.09, 0.20)%]. At 6 months, the effect on HbA
 
1c
 
 was greater with add-on
sulphonylurea, but was similar whether sulphonylurea was added to rosiglitazone or
metformin. Differences in fasting plasma glucose were not statistically significant at
18 months [rosiglitazone vs. sulphonylurea 
 
−
 
0.36 (
 
−
 
0.74, 0.02) mmol/l, rosiglita-
zone vs. metformin 
 
−
 
0.34 (
 
−
 
0.73, 0.05) mmol/l]. Increased homeostasis model
assessment insulin sensitivity and reduced C-reactive protein were greater with
rosiglitazone than metformin or sulphonylurea (all 
 
P
 
 
 
≤
 
 0.001). Body weight
was significantly increased with rosiglitazone compared with sulphonylurea
[difference 1.2 (0.4, 2.0) kg, 
 
P
 
 
 
=
 
 0.003] and metformin [difference 4.3 (3.6, 5.1) kg,
 
P
 
 
 
<
 
 0.001].
 
Conclusions
 
In people with diabetes, rosiglitazone in combination with metformin
or sulphonylurea was demonstrated to be non-inferior to the standard combination
of metformin 
 
+
 
 sulphonylurea in lowering HbA
 
1c
 
 over 18 months, and produces
greater improvements in C-reactive protein and basal insulin sensitivity but is
also associated with greater weight gain.
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Abbreviations 
 
AE, adverse event; BMI, body mass index; CRP, C-reactive protein;
CV, cardiovascular; FPG, fasting plasma glucose; HDL, high-density lipoprotein;
HOMA, homeostasis model assessment; hPI, intact human proinsulin; ITT, intention
to treat; LDL, low-density lipoprotein; NEFA, non-esterified fatty acids; PAI-1,
plasminogen activator inhibitor-1; RECORD, Rosiglitazone Evaluated for Cardiac
Outcomes and Regulation of glycaemia in Diabetes; UKPDS, UK Prospective
Diabetes Study
 
Introduction
 
The major therapeutic management goals for people with
Type 2 diabetes are achieving optimal control of glycaemia,
lipid levels and blood pressure to reduce the risk of long-
term vascular complications. Treatment algorithms for the
management of glycaemia have advocated a step-wise approach
with diet and exercise as first-line management, followed by the
addition of oral glucose-lowering agents [1]. Drug monotherapy
may prove effective initially, but in the face of progressively
declining islet B-cell function, the hallmark of diabetes [2,3],
half the population requires combination therapy within
3 years of diagnosis [4].
The progressive nature of Type 2 diabetes, coupled with rising
prevalence [5] and better adherence to HbA
 
1c
 
 targets, means
that increasing numbers of people with diabetes are taking
combination therapies. However, whilst clinical trials comparing
glucose-lowering drugs in monotherapy are relatively common,
longer-term comparisons of new dual-agent combinations with
the de facto standard of metformin 
 
+
 
 sulphonylurea are rare.
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation
of glycaemia in Diabetes (RECORD), a 6-year, multicentre,
randomized, open-label, parallel-group study of cardiovascular
outcomes [6], presents an opportunity to compare rosiglitazone 
 
+
 
metformin and rosiglitazone 
 
+
 
 sulphonylurea with metformin 
 
+
 
sulphonylurea therapy in a large population of people with
Type 2 diabetes. This paper presents a prospectively defined
analysis of glucose control at 18 months in the first 1122
RECORD participants. It is the first head-to-head comparison
of the two rosiglitazone-containing treatment regimens
against metformin 
 
+
 
 sulphonylurea.
 
Patients and methods
 
Participants
 
The RECORD protocol is described in detail elsewhere [6].
RECORD involves 330 centres in 23 countries in Europe,
Australia and New Zealand. A total of 4458 individuals with
Type 2 diabetes, inadequately controlled on metformin or
sulphonylurea, have enrolled (Fig. 1). The current pre-specified
18-month analysis is based on data collected for the first 1122
people randomized until 15 April 2002 (598 people already on
sulphonylurea; 524 already on metformin). Eligible participants
had Type 2 diabetes as defined by the 1999 World Health
Organization criteria [7], were aged 40–75 years, with body
mass index (BMI) 
 
>
 
 25.0 kg/m
 
2
 
, HbA
 
1c
 
 
 
>
 
 7.0–9.0%, and thus
inadequately controlled on maximum permitted or tolerated
doses of metformin or a sulphonylurea (glyburide, glimepiride
or gliclazide) at study entry.
The study is conducted according to Good Clinical Practice
guidelines and the Declaration of Helsinki [8]. The protocol
was approved by Ethics Review Committees/Institutional
Review Boards according to the local laws/customs of each
participating country. Written informed consent was obtained
from participants before beginning protocol-specific procedures.
 
Study design
 
RECORD is a multicentre, randomized, open-label, comparative,
parallel-group trial. Eligible participants continued to take the
oral glucose-lowering drug (metformin or sulphonylurea) they
were taking prior to study entry and entered a 4-week run-in
period, which included reinforcement of lifestyle education,
followed by randomization to additional treatment with add-
on study medication. Treatment allocation, using a concealed
remote telephone system, was stratified for prior glucose-
lowering drug: people on a sulphonylurea randomized to either
add-on rosiglitazone or metformin; those on metformin to
rosiglitazone or sulphonylurea [glibenclamide (glyburide;
normal/micronized), gliclazide, or glimepiride, chosen according
to local practice]. Allocated drugs were non-blinded owing to the
difficulties of arranging six preparations with different dosing
schedules, and the impossibility of maintaining blinded allocation
with asymmetric timing of insulin therapy initiation.
Throughout the study, participants were managed to target
HbA
 
1c
 
 
 
≤
 
 7.0%. The randomized starting dose for rosiglitazone
was 4 mg/day and those for metformin and sulphonylurea were
in accordance with local clinical practice. If HbA
 
1c
 
 rose to 
 
>
 
 7.0%
after 8 weeks of randomized treatment, the dose of randomized
study medication was increased towards a maximum of 4 mg
rosiglitazone twice daily, 2550 mg metformin, 15 mg glyburide
(or equivalent for micronized preparation), 240 mg gliclazide,
or 4 mg glimepiride. If HbA
 
1c
 
 was 
 
≥
 
 8.5% (confirmed by a second
measurement at least 1 month later) on the maximum tolerated
dose for at least 8 weeks, a third glucose-lowering agent could
be added if on rosiglitazone, or insulin initiated if on metformin 
 
+
 
sulphonylurea.
 
Efficacy assessments
 
The primary analysis of glycaemic control was change from
baseline in HbA
 
1c
 
 after 18 months’ randomized treatment.
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Secondary efficacy analyses included fasting plasma glucose
(FPG), serum lipids, homeostasis model assessment (HOMA)
basal insulin sensitivity and islet B-cell function (HOMA %B)
by the equation method [9], and inflammatory/thrombotic
markers [plasminogen activator inhibitor-1 (PAI-1) antigen,
fibrinogen, and C-reactive protein (CRP)]. HbA
 
1c
 
, FPG and
body weight were assessed at baseline and all eight follow-up
visits; lipids at baseline, 6, 12 and 18 months; and other measures
at baseline, 12 and 18 months. As RECORD was ongoing at
the time of this 18-month analysis, safety and adverse event
(AE) data including some aspects of body weight/oedema and
hypoglycaemia were not analysed in order to maintain the
integrity of the main study.
 
Laboratory methods
 
A central laboratory was used for all routine laboratory assess-
ments (Quest Diagnostics, Heston, UK). HbA
 
1c
 
 was measured
by HPLC using Diabetes Control and Complications Trial
(DCCT)-standardized Biorad Variant HbA
 
1c
 
 assay (Bio-Rad
Laboratories, Hercules, CA, USA). FPG concentration was
measured using an enzymatic method. Serum insulin (kit from
Perkin Elmer, Turku, Finland) was determined by a specific
two-site fluoroimmunometric assay [cross-reactivity with
proinsulin: intact human proinsulin (hPI) 0.1%, des 32,33 hPI
0.4%, des 64,65 hPI 66%]. Intact proinsulin was measured
using a two-site fluoroimmunometric assay (typically 
 
<
 
 1% cross-
reaction with insulin and 32–33 split proinsulin at 2500 pmol/l
and 400 pmol/l, respectively; no detectable cross-reaction with
C-peptide]. Total and high-density lipoprotein (HDL) cholesterol
were analysed by Olympus cholesterol esterase assays (Olympus
UK, Southall, UK), and low-density lipoprotein (LDL) cholesterol
was calculated using the Friedewald equation. Triglycerides
were measured by enzymatic determination of glycerol using
Olympus reagents. Non-esterified fatty acids (NEFA) were
measured by enzymatic colorimetric assay (Wako Chemicals,
Neuss, Germany). PAI-1 antigen was quantified using a Biopool
TintElize (Ventura, CA, USA) enzyme immunoassay kit. Highly
sensitive CRP was measured by fixed-time nephelometry (Dade
Behring, Milton Keynes, UK) and fibrinogen by photo-optical
clot detection in plasma on adding thrombin.
 
Statistical analysis
 
The primary objective was to test whether the 18-month mean
change from baseline HbA
 
1c
 
 for the intention-to-treat (ITT)
population (all randomized, treated and with at least one data
FIGURE 1  Flow diagram of the study design. This diagram includes 11 participants whose completer status was unknown at the time the database was 
locked for analysis, but whose status was subsequently established. *For definition of intention-to-treat (ITT) population, see text. †Includes people 
who moved to the Post-Randomized Treatment phase of the study, and people who withdrew completely. ‡‘Other’ reasons include lost to follow-up, 
consent withdrawn, sponsor terminated, non-compliance and miscellaneous reasons, including one on metformin + rosiglitazone group with 
ALT > 3 × upper limit of normal. §Two participants on sulfonylurea + metformin withdrew because of an adverse event in error, later resumed assigned 
therapy, and are not included as ‘withdrawn’. OGLD, oral glucose-lowering drug.
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point post-randomization) with rosiglitazone oral combination
therapy was at least as good as the respective controls receiving
metformin 
 
+
 
 sulphonylurea. The non-inferiority criterion
(upper bound 95% CI of difference) was preset at 0.4 % units.
With 260 participants per arm and change from baseline 
 
SD
 
 of
1.4% (actual 
 
∼
 
1.0%), the study was estimated to have 90%
power.
The primary ITT analysis of treatment difference at 18 months
was by repeated-measures analysis (based on all available data)
using a model including terms for treatment and baseline by
visit interaction, using an unstructured covariance matrix to
model the within-patient variability for each treatment group.
A supportive per-protocol analysis excluding participants with
prospectively defined major protocol deviations at baseline
(principally regarding background glucose-lowering treatment
and HbA
 
1c
 
) or during the 18-month treatment period (use of
prohibited medication, non-compliance with the treatment
algorithm) was also performed. Participants who stopped
dual-combination therapy, including those who progressed to
triple-combination therapy or started insulin, had their data
censored from the time dual-combination therapy was stopped.
Analyses of FPG and body weight data used the same methodology
as for HbA
 
1c
 
.
A responder analysis, including the proportion of participants
with a reduction in HbA
 
1c
 
 
 
≥
 
 0.7% and the proportion achieving
a predefined target of 
 
≤
 
 7.0%, both at 18 months, compared
treatment groups using logistic regression modelling with treatment
and baseline HbA
 
1c
 
 as factors. Conservatively, people with
missing data at 18 months were taken as non-responders.
For fasting insulin, proinsulin, proinsulin:insulin ratio,
HOMA estimates of insulin sensitivity and islet B-cell function,
and for inflammatory/thrombotic markers, summary statistics
using log-transformed data were produced. Between-group
differences within each stratum were calculated at 18 months
for insulin sensitivity and inflammatory/thrombotic markers
using 
 
ANCOVA
 
 on observed case data at 18 months, adjusted for
baseline value. This methodology was also used for analyses of
lipid parameters using untransformed data.
All significance tests and confidence intervals were two-sided
and performed or constructed at the 5% significance level.
Analyses were conducted using SAS for Windows (version 8.2;
SAS Institute, Cary, NC, USA).
 
Results
 
Baseline characteristics and withdrawals
 
Baseline characteristics were well matched between randomized
groups within the background metformin and background
sulphonylurea strata (Table 1). However, participants in the
background metformin stratum had lower age, higher BMI and
a shorter duration since diagnosis than those in the background
sulphonylurea stratum.
Table 1 Clinical and baseline characteristics of the population studied
Background metformin Background sulphonylurea 
Rosiglitazone Sulphonylurea Rosiglitazone Metformin
Patients (n) 259 265 311 284
Age (years) 57 ± 8 57 ± 8 61 ± 8 60 ± 8
Male [n (%)] 141 (54) 139 (52) 152 (49) 149 (52)
Europid [n (%)] 257 (99) 263 (99) 309 (99) 281 (99)
Time from diagnosis (years) 6.1 ± 4.3 7.0 ± 5.6 7.9 ± 5.7 8.1 ± 5.4
Body weight (kg) 93 ± 17 91 ± 15 84 ± 14 83 ± 12
Body mass index (kg/m2) 32.7 ± 5.4 32.3 ± 4.8 30.1 ± 3.8 29.8 ± 3.9
HbA1c (%) 7.9 ± 0.70 7.8 ± 0.66 8.0 ± 0.69 8.0 ± 0.77
Fasting plasma glucose (mmol/l) 9.7 ± 2.38 9.7 ± 2.23 10.2 ± 2.54 10.1 ± 2.24
Homeostasis model assessment %B (%) 30.6 (19.5, 44.2) 30.9 (17.6, 47.3) 24.3 (15.9, 37.9) 22.2 (14.2, 36.8)
Homeostasis model assessment %S (%) 29 (19, 43) 30 (17, 45) 29 (20, 45) 32 (21, 49)
C-reactive protein (mg/l) 3.6 (1.7, 7.2) 3.0 (1.4, 7.1) 2.5 (1.3, 4.6) 2.9 (1.2, 5.2)
Plasminogen activator inhibitor-1 antigen (µg/l) 60 (39, 84) 55 (38, 87) 60 (40, 91) 62 (40, 92)
Fibrinogen (g/l) 3.2 (2.8, 3.7) 3.2 (2.7, 3.6) 3.2 (2.8, 3.7) 3.3 (2.9, 3.8)
Insulin (pmol/l) 61 (41, 89) 57 (39, 97) 57 (36, 80) 53 (34, 71)
Proinsulin (pmol/l) 9.1 (5.8, 16.0) 9.6 (6.3, 15.7) 11.8 (7.7, 19.6) 10.9 (7.0, 17.5)
Proinsulin:insulin ratio (pmol/pmol) 0.16 (0.10, 0.25) 0.16 (0.10, 0.25) 0.23 (0.14, 0.36) 0.23 (0.15, 0.36)
Total cholesterol (mmol/l) 5.4 ± 0.92 5.4 ± 1.02 5.6 ± 1.04 5.6 ± 1.09
Triglycerides (mmol/l) 2.2 ± 1.11 2.1 ± 1.32 2.1 ± 1.88 2.1 ± 1.45
High-density lipoprotein cholesterol (mmol/l) 1.2 ± 0.27 1.2 ± 0.28 1.2 ± 0.31 1.2 ± 0.32
Low-density lipoprotein cholesterol (mmol/l) 3.2 ± 0.79 3.2 ± 0.84 3.5 ± 0.87 3.5 ± 0.96
Non-esterified fatty acids (mmol/l) 0.63 ± 0.22 0.63 ± 0.24 0.66 ± 0.25 0.64 ± 0.24
Number (%), mean ± SD, or median (IQR).
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All but three participants began their randomized medication;
202 were withdrawn before 18 months. More participants
in the metformin 
 
+
 
 rosiglitazone group (20%) ceased dual-
combination therapy than in the metformin 
 
+
 
 sulphonylurea
group (8%; Fig. 1). More participants in the metformin 
 
+
 
rosiglitazone group progressed to triple therapy (10%) than
those to insulin in the metformin 
 
+
 
 sulphonylurea group (2%).
Similar proportions of participants in the sulphonylurea 
 
+
 
rosiglitazone and sulphonylurea 
 
+
 
 metformin groups ceased
dual-combination treatment (24 and 19%, respectively), but
more patients in the sulphonylurea 
 
+
 
 rosiglitazone group
progressed to triple therapy (11%) than those to insulin in
the sulphonylurea 
 
+
 
 metformin group (4%), while more
people in the sulphonylurea 
 
+
 
 metformin group (7%) than the
sulphonylurea 
 
+
 
 rosiglitazone group (1%) stopped randomized
treatment as a result of an AE (Fig. 1).
 
Glucose control end points
 
At 18 months, the reductions in HbA
 
1c
 
 in the rosiglitazone
groups were similar to those achieved in the respective control
groups (Table 2). In both strata, the upper limit of the 95% CI
for the treatment difference was 0.2%, half the criterion for
non-inferiority. The results of the per-protocol analysis
supported the ITT analysis (data not shown).
In the background metformin stratum, the HbA
 
1c
 
 response
was more rapid with sulphonylurea than rosiglitazone (Fig. 2),
with a significant mean adjusted treatment difference (
 
P 
 
<
 
 0.001)
in favour of metformin 
 
+
 
 sulphonylurea at 6 months [difference
0.37 (95% CI 0.25, 0.49)%]. However, this superiority was
not sustained beyond 8–12 months (Fig. 2) and, at 18 months,
the mean adjusted treatment difference was no longer signifi-
cant between the two groups (Table 2). In the background
sulphonylurea stratum, the trajectory of HbA1c reduction was
similar for rosiglitazone and metformin groups (Fig. 2), with
no significant differences at 6 or 18 months.
A reduction in HbA1c ≥ 0.7% from baseline was achieved
at 18 months in 35 and 45% of the background metformin
participants on rosiglitazone and sulphonylurea, respectively
[odds ratio (OR) 0.62 (95% CI 0.42, 0.90), P = 0.012] and 45
and 37% of background sulphonylurea participants using
rosiglitazone and metformin [OR 1.47 (1.02, 2.10), P = 0.037].
FIGURE 2  Time course for HbA1c (upper panels) and fasting plasma glucose (FPG; lower panels) during the 18-month treatment period. Data are 
model adjusted mean ± SE. Left-hand panels show addition of rosiglitazone (; n = 253) or sulfonylurea (; n = 263) to metformin; right-hand panels 
show addition of rosiglitazone (; n = 301) or metformin (; n = 272) to sulfonylurea.
dme_2160.fm  Page 630  Thursday, May 17, 2007  2:50 PM
O
riginal article
D
IA
B
ETIC
M
edicine
©
 2007 The A
uthors.
Journal com
pilation ©
 2007 D
iabetes U
K
. D
iabetic M
edicine, 24, 626–
634
631
Table 2 Change from baseline at 18 months in measures of glucose control, insulin sensitivity, body weight, inflammatory/thrombotic markers and lipid measures
Background metformin Background sulphonylurea 
Rosiglitazone vs. Sulphonylurea Rosiglitazone vs. Metformin
ITT population (n) 253 263 301 272
Completers (n) 202 240 236 226
HbA1c (%)
Change −0.48 (−0.59, −0.36) −0.55 (−0.66, −0.44) −0.55 (−0.67, −0.44) −0.61 (−0.70, −0.51)
Difference, P 0.07 (−0.09, 0.23), NS 0.06 (−0.09, 0.20), NS
Fasting plasma glucose (mmol/l)
Change −1.5 (−1.78, −1.29) −1.2 (−1.46, −0.89) −2.0 (−2.26, −1.66) −1.6 (−1.87, −1.36)
Difference, P −0.36 (−0.74, 0.02), 0.062 −0.34 (−0.73, 0.05), 0.089
Homeostasis model assessment %B (% baseline)
Change 13.4 (4.2, 23.3) 38.8 (28.3, 50.1) 33.0 (22.2, 44.7) 25.4 (15.1, 36.6)
Difference, P −18.3 (−27.2, −8.4), < 0.001 6.1 (−6.0, 19.7), NS
Homeostasis model assessment %S (% baseline)
Change 56 (42, 70) 11 (2, 20) 65 (53, 77) 36 (26, 46)
Difference, P 40 (25, 58), < 0.001 21 (10, 34), < 0.001
Body weight (kg)
Change 2.3 (1.7, 2.9) 1.1 (0.6, 1.6) 3.4 (2.9, 4.0) −0.9 (−1.4, −0.4)
Difference, P 1.2 (0.4, 2.0), 0.003 4.3 (3.6, 5.1), < 0.001
C-reactive protein (% baseline)
Change −41 (−48, −33) −6 (−17, 6) −36 (−43, −28) −16 (−26, −6)
Difference, P −37 (−47, −24), < 0.001 −24 (−35, −10), 0.001
Plasminogen activator inhibitor-1 antigen (% baseline)
Change −5.7 (−13.9, 3.3) 7.0 (−1.7, 16.4) −11.1 (−18.5, −3.1) −11.2 (−18.7, −3.0)
Difference, P −12 (−22, −0.2), 0.047 0 (−12, 13), NS
Fibrinogen (% baseline)
Change 2.1 (−0.9, 5.1) 10.9 (7.9, 14.0) 3.2 (0.9, 5.7) 7.3 (4.7, 9.9)
Difference, P −8.0 (−11.6, −4.2), 0.001 −3.8 (−7.0, −0.5), 0.024
Total cholesterol (mmol/l)
Change 0.37 (0.23, 0.51) −0.16 (−0.29, −0.03) 0.46 (0.33, 0.59) −0.10 (−0.24, 0.04)
Difference, P 0.53 (0.34, 0.71), < 0.001 0.56 (0.36, 0.75), 0.001
Triglycerides (mmol/l)
Change 0.40 (0.25, 0.55) 0.15 (0.01, 0.29) 0.24 (0.06, 0.42) 0.17 (−0.02, 0.36)
Difference, P 0.26 (0.05, 0.47), 0.016 0.06 (−0.20, 0.32), NS
High-density lipoprotein cholesterol (mmol/l)
Change 0.08 (0.05, 0.11) 0.02 (−0.01, 0.05) 0.10 (0.07, 0.13) 0.08 (0.05, 0.11)
Difference, P 0.06 (0.02, 0.10), 0.001 0.01 (−0.02, 0.05), NS
Low-density lipoprotein cholesterol (mmol/l)
Change 0.04 (−0.07, 0.15) −0.26 (−0.36, −0.16) 0.19 (0.08, 0.30) −0.29 (−0.40, −0.18)
Difference, P 0.30 (0.16, 0.45), 0.000 0.48 (0.32, 0.64), 0.000
Non-esterified fatty acids (mmol/l)
Change −0.07 (−0.10, −0.04) 0.04 (0.01, 0.07) −0.06 (−0.10, −0.02) 0.06 (0.02, 0.10)
Difference, P −0.11 (−0.15, −0.06), 0.000 −0.12 (−0.17, −0.07), 0.000
Data are model-adjusted mean (95% CI), or number.
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An HbA1c ≤ 7.0% at 18 months was achieved by 35 and 39%
of participants comparing rosiglitazone with sulphonylurea,
and 37 and 31% comparing rosiglitazone with metformin
(both comparisons NS).
At 18 months, the apparently greater reductions in FPG in
the rosiglitazone groups did not reach statistical significance
(Table 2). On background metformin, FPG fell rapidly after
initiating a sulphonylurea (within 2 months) but this advan-
tage was lost by 6 months (Fig. 2). In both rosiglitazone
groups, initial FPG reduction was slower, steadying at 6–
8 months. Metformin + sulphonylurea showed a similar
trajectory to the rosiglitazone groups (Fig. 2).
Insulin sensitivity and islet B-cell function
In both background treatment strata, 18-month HOMA-
estimated basal insulin sensitivity was substantially increased
in the rosiglitazone groups compared with the respective
controls (both P < 0.001; Table 2). The effect of metformin on
insulin sensitivity was about half that of rosiglitazone. Both
rosiglitazone and sulphonylurea when added to metformin
increased HOMA %B, but this increase was greater with
sulphonylurea (P < 0.001; Table 2). Rosiglitazone or metformin
added to background sulphonylurea also increased HOMA %B,
and to a similar extent (Table 2).
At 18 months in both strata, rosiglitazone-treated patients
had greater mean reductions in fasting plasma insulin than
the respective controls [metformin strata: rosiglitazone −11.1
(−17.5, −4.7) vs. sulphonylurea 4.4 (−1.5, 10.3) pmol/l;
sulphonylurea strata: rosiglitazone −15.4 (−19.8, −11.1) vs.
metformin −5.9 (−9.4, −2.5) pmol/l]. Similar differences were
obtained for proinsulin for rosiglitazone vs. sulphonylurea
[−4.8 (−6.0, −3.5) vs. 1.8 (0.4, 3.1) pmol/l], but with overlap
for the rosiglitazone vs. metformin groups [−6.4 (−9.2, −3.7)
vs. −3.5 (−4.7, −2.3) pmol/l]. Rosiglitazone resulted in a greater
reduction in proinsulin:insulin ratio than sulphonylurea
[−22.3 (−28.9, −15.1) vs. 0.9 (−6.6, 9.1)%], whereas similar
decreases were observed when rosiglitazone was contrasted
with metformin [−15.0 (−21.3, −8.2) vs. −17.1 (−23.5, −10.2)%].
Body weight
Increases in body weight were observed in both arms of the
metformin stratum; however, this increase was greater with
rosiglitazone than sulphonylurea (P = 0.003; Table 2). In the
sulphonylurea stratum there was a significant increase in body
weight with rosiglitazone compared with a slight decrease
with metformin (P < 0.001).
Lipids and inflammatory/thrombotic markers
In both background treatment strata, rosiglitazone increased
total cholesterol and LDL cholesterol and reduced NEFA at
18 months compared with control groups (Table 2). An
increase in HDL cholesterol and triglycerides was observed
with rosiglitazone compared with sulphonylurea (0.08 vs.
0.02 mmol/l, P = 0.001; 0.40 vs. 0.15 mmol/l, P = 0.016,
respectively), but not with metformin (Table 2).
At 18 months, PAI-1 antigen decreased from baseline with
rosiglitazone, with a significant difference compared with
sulphonylurea (−5.7 vs. 7.0%, P = 0.047; Table 2); rosiglitazone
and metformin did not differ (Table 2). In both rosiglitazone
groups, there were statistically significant reductions in CRP
compared with respective controls (Table 2), even against
metformin + sulphonylurea which showed a small fall from
baseline. The level of fibrinogen increased in all treatment
groups, but the magnitude of the increase was significantly
smaller in the rosiglitazone groups compared with controls,
with the greatest contrast against sulphonylurea (Table 2).
Discussion
This pre-defined sub-study of RECORD has the strength of
being the first randomized clinical trial to compare add-on
rosiglitazone combination therapy with both sulphonylureas
and metformin against the standard combination of metformin +
sulphonylurea, across a wide range of surrogate outcomes.
Other strengths of the study include its size and longer-term
duration, together with a wide population base. Weaknesses
include the open-label design and the exclusion of clinically
significant data, including AEs, reporting of which might
affect the integrity of the underlying 6-year study. Similar data
for people with poor blood glucose control have recently been
published for pioglitazone [10]. Importantly, average blood
glucose control at entry to the current study on metformin or
sulphonylurea therapy was not too poor, and the dose of study
medication was not fixed or force-titrated, but adjusted to
achieve target HbA1c ≤ 7.0%. This was in line with some
guidelines at the time of study design, and is such that the
glucose control achieved, if not optimal, appears not untypical
of current clinical practice.
The primary outcome findings from the study demonstrate
that following 18 months’ treatment a similar degree of overall
glucose-lowering efficacy is achieved with add-on rosiglitazone
as that achieved with add-on metformin and sulphonylurea.
As the improvement of HbA1c in the two arms was the same
with rosiglitazone, the study also suggests that metformin and
sulphonylureas have similar glucose-lowering efficacy after
1.5 years. None of these observations excludes the possibility
that there are sub-populations or individuals in whom the
efficacy of the drugs will differ.
However, the rate of change of glucose-lowering efficacy
does differ among the three drugs, the data presented being
consistent with previous studies [10]. Thus, the sulphonylureas
have a rapid onset of action and effect on direct blood glucose
measurements (FPG in Fig. 2), but a rate of fall of HbA1c
which, allowing for kinetics of glycated haemoglobin turnover,
suggests nearly instantaneous effects on blood glucose control.
Rosiglitazone, as pioglitazone, has a much slower onset of
effect; this is also true, although not generally appreciated in
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clinical practice, of metformin (Fig. 2). It seems reasonable to
suggest that the effects of sulphonylureas in stimulating insulin
secretion are nearly instantaneous, but that restoration of insulin
sensitivity with the thiazolidinediones takes time.
The effect of sulphonylureas, however, is not sustained, the
data here being consistent with studies showing improvement
then waning of islet B-cell function over the first 10 months’
therapy [10]. Accordingly, despite the improvement in blood
glucose control persisting to 18 months, and presumably still
reflecting improved pancreatic function [11], proinsulin and
proinsulin:insulin were unchanged with sulphonylureas, but
improved with rosiglitazone and metformin. In the longer term
(3–6 years), metformin and sulphonylureas are associated
with similar rates of loss of islet B-cell function [11], but the
more rapid loss of function with sulphonylureas after the initial
gain is not understood. Long-term data for rosiglitazone will
be an outcome of the RECORD study at its 6-year termina-
tion, and have recently become available from the ADOPT
study for people with lesser degrees of impaired glucose
metabolism [12].
Reductions in FPG observed with rosiglitazone were generally
greater than would be predicted from the change in HbA1c.
This might be explained by a greater effect on postprandial
glycaemia by metformin and/or sulphonylurea, but this
hypothesis cannot be tested within this study as no postprandial
measurements were made. The extent of the HbA1c reduction
at 18 months (0.5–0.6%), from baseline levels of 7.8–8.0%,
explains the small proportion of participants reaching the
conservative glucose control target by 18 months. If current
guideline targets from International Diabetes Federation (IDF)
and American College of Endocrinologists (ACE)/American
Association of Clinical Endocrinologists (AACE) are to be met
[1,13], this emphasizes that combination therapy will need to
be initiated early in the clinical history of most people with
diabetes and measures to achieve this, such as guideline
implementation initiatives and combination tablets, need
further study. In the present study, despite the similar mean
18-month HbA1c, differences were observed in responder
rates, with more rosiglitazone than metformin participants
achieving a reduction of ≥ 0.7% in the sulphonylurea stratum,
while fewer so responded on rosiglitazone than sulphonylurea
in the metformin stratum. The apparent inconsistency with
mean HbA1c may in part be explained by some non-normality
in all groups, and the conservative assumptions made about
those with missing data in the responder analysis. The non-
normality may have arisen from there being subgroups of people
who respond better to one drug or the other, but confirmation
of this by other large trials would be needed.
The number of participants moving off dual-combination
treatment was higher for the rosiglitazone groups than the
respective control groups. This was particularly noticeable for
the sulphonylurea comparison, and may reflect the early and
rapid effect of these drugs noted above, particularly as the
entry criteria for HbA1c (< 9.0%) were above the threshold
for discontinuation (8.5%). Additionally, this was an open
asymmetric study [6], where the comparator groups move to
insulin while the rosiglitazone group has another oral agent
added. This is likely to have inhibited the comparator groups
from ceasing oral combination therapy [14,15].
The improvements observed with rosiglitazone in insulin
sensitivity have previously been reported in other smaller,
shorter studies [16–19], and with pioglitazone. Interestingly,
the effect of metformin was much lower, even though this
drug is sometimes termed an insulin sensitizer, implying
that the effect of metformin on glucose-lowering involves
mechanisms other than improving hepatic performance in
response to insulin. There was no evidence of a secondary
effect of sulphonylureas on basal insulin sensitivity. These
improvements in insulin sensitivity were observed in the face
of substantial weight gain with rosiglitazone. This apparent
paradox is a well-known feature of thiazolidinedione
pharmacology and may be related to preferential deposition of
subcutaneous and not visceral fat [18,20]. It is known from the
UK Prospective Diabetes Study (UKPDS) that metformin
improves HOMA estimates of islet B-cell function, although to
a much smaller degree than sulphonylureas, but the mechanism
(reduction in glucose toxicity or reduction in demand on the
islet B-cell) is not known. A similar change is shown here for
rosiglitazone.
Although there were no restrictions on the initiation or
continued use of lipid-lowering therapy in RECORD, this does
not appear to have substantially confounded the assessment of
18-month lipid end points, as they confirmed the previously
reported effects of rosiglitazone in increasing total, LDL and
HDL cholesterol [21]. The significance of the changes in LDL
and thus total cholesterol remain difficult to interpret after use
of thiazolidinediones, because the nature of the LDL lipoprotein
particles is markedly changed by these drugs to a less-dense
phenotype [22].
The improvements in CRP, PAI-1 antigen, and fibrinogen
observed with rosiglitazone combination therapy are also
consistent with previous monotherapy data [23,24], and are
shown to be sustained. Metformin again affected CRP, albeit
much less than rosiglitazone; both had the same effect on PAI-1.
Sulphonylureas were not active in these respects, or possibly
(for PAI-1) worsened this prothrombotic marker. Given that
these three measures are risk markers for cardiovascular (CV)
events in people with Type 2 diabetes [25–27], and given that
metformin appears to prevent CV events beyond what can be
predicted by its glucose-lowering effect, the results of the CV
outcomes phase of RECORD will be awaited with interest,
particularly in the light of the findings in the PROspective
PioglitAzone Clinical Trial In MacroVascular Events (PROactive)
study [28].
In conclusion, after 18 months’ treatment, rosiglitazone in
combination with metformin or sulphonylurea, is as effective
in lowering HbA1c in people with Type 2 diabetes as the standard
combination of metformin + sulphonylurea, and produces
greater improvements in CRP and insulin sensitivity but is also
associated with greater weight gain.
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